PA8846801A1 - Composiciones farmacéuticas que contienen diacereína - Google Patents

Composiciones farmacéuticas que contienen diacereína

Info

Publication number
PA8846801A1
PA8846801A1 PA20098846801A PA8846801A PA8846801A1 PA 8846801 A1 PA8846801 A1 PA 8846801A1 PA 20098846801 A PA20098846801 A PA 20098846801A PA 8846801 A PA8846801 A PA 8846801A PA 8846801 A1 PA8846801 A1 PA 8846801A1
Authority
PA
Panama
Prior art keywords
pharmaceutical compositions
compositions containing
diacerein
containing diacerein
treat
Prior art date
Application number
PA20098846801A
Other languages
English (en)
Inventor
Gao Danchen
Wu Jen-Sen
Wei-Shu-Lu
Chen Shouchiung
Kuo Pei-Chun
Chen Chih-Ming
Original Assignee
Anchen Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anchen Lab Inc filed Critical Anchen Lab Inc
Publication of PA8846801A1 publication Critical patent/PA8846801A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/2853Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE DIVULGA UNA ÚNICA FORMULACIÓN DIARIA DE LIBERACIÓN CONTROLADA DE DIACEREÍNA PARA TRATAR ENFERMEDADES INFLAMATORIAS O AUTOINMUNES O SUS COMPLICACIONES, CON EFECTOS COLATERALES ADVERSOS REDUCIDOS, Y MÉTODOS PARA TRATAR DICHAS ENFERMEDADES.
PA20098846801A 2008-10-28 2009-10-28 Composiciones farmacéuticas que contienen diacereína PA8846801A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10893108P 2008-10-28 2008-10-28

Publications (1)

Publication Number Publication Date
PA8846801A1 true PA8846801A1 (es) 2010-05-26

Family

ID=42117735

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20098846801A PA8846801A1 (es) 2008-10-28 2009-10-28 Composiciones farmacéuticas que contienen diacereína

Country Status (19)

Country Link
US (2) US20100104651A1 (es)
EP (1) EP2349289B1 (es)
JP (1) JP5642691B2 (es)
KR (1) KR101718347B1 (es)
CN (1) CN102202673B (es)
AR (1) AR073918A1 (es)
AU (1) AU2009308958B2 (es)
BR (1) BRPI0920255A2 (es)
CA (1) CA2741846C (es)
ES (1) ES2585904T3 (es)
IL (1) IL212483A (es)
MX (1) MX2011004395A (es)
NZ (1) NZ592376A (es)
PA (1) PA8846801A1 (es)
RU (1) RU2542461C2 (es)
SA (1) SA109300644B1 (es)
TW (1) TWI473610B (es)
UY (1) UY32204A (es)
WO (1) WO2010051296A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012024936A2 (pt) * 2010-04-08 2015-09-15 Twi Biotechnology Inc uso de diacereína ou de um sal, um análogo, uma prodroga, ou um metabólito ativo farmaceuticamente aceitável do mesmo
CN101822660B (zh) * 2010-05-13 2013-07-10 中国人民解放军肾脏病研究所 大黄酸类化合物或其盐在制备预防和治疗胰岛β细胞功能衰退药物中的应用
RU2603050C2 (ru) * 2011-03-11 2016-11-20 ТиДаблЮАй БАЙОТЕКНОЛОДЖИ, ИНК. Способы и композиции для лечения гиперурикемии и метаболических нарушений, связанных с гиперурикемией
CN102743370B (zh) * 2011-06-27 2013-05-15 王子厚 双醋瑞因的用途
US9757424B2 (en) 2011-09-27 2017-09-12 Biomed Valley Discoveries, Inc. Compositions and methods of treating gliomas
WO2013100881A2 (en) * 2011-12-27 2013-07-04 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Combined pharmaceutical formulation containing diacerein
EA201491039A1 (ru) * 2011-12-27 2015-02-27 Сановел Илач Санайи Ве Тиджарет Аноним Ширкети Комбинации диацереина и нестероидных противовоспалительных лекарственных средств
CN102871982B (zh) * 2012-10-16 2014-09-10 中国科学院上海药物研究所 一种药物渗透泵制剂
WO2014153241A1 (en) 2013-03-14 2014-09-25 The Regents Of The University Of Michigan Treatment of staphylococcal disorders
MX2017013489A (es) * 2015-04-20 2018-05-22 Twi Biotechnology Inc Formulaciones que contienen diacereina y metodos para la reduccion de los niveles en sangre de acido urico usando los mismos.
US10512625B2 (en) * 2015-07-01 2019-12-24 Twi Biotechnology, Inc. Diacerein or rhein topical formulations and uses thereof
US10154984B2 (en) * 2015-07-01 2018-12-18 Twi Biotechnology, Inc. Diacerein or Rhein topical formulations and uses thereof
US9744131B2 (en) * 2015-07-01 2017-08-29 Twi Biotechnology, Inc. Diacerein or rhein topical formulations and uses thereof
TWI743047B (zh) * 2015-08-17 2021-10-21 安成生物科技股份有限公司 使用雙醋瑞因或其類似物抑制asc表現、nlrp3表現、以及/或nlrp3發炎體複合物的形成之方法
JP7084930B2 (ja) * 2017-01-18 2022-06-15 タイレックス, インコーポレーテッド 炎症性腸疾患及び腸管大腸炎を処置するのに使用するための組成物
WO2018136706A1 (en) 2017-01-19 2018-07-26 Twi Biotechnology, Inc. Methods and pharmaceutical compositions for preventing or treating immunoinflammatory dermal disorders
CN107929264B (zh) * 2017-12-04 2020-04-24 广东药科大学 双醋瑞因缓释微球及其制备方法
KR102075724B1 (ko) * 2018-09-14 2020-02-10 한국원자력의학원 디아세레인을 유효성분으로 포함하는 항체의 종양 침투력 증진용 조성물 및 이의 용도
CN117017959A (zh) 2018-11-14 2023-11-10 珠海岐微生物科技有限公司 用于眼内疾病或病症的动物模型、筛选方法和治疗方法
CN110787157A (zh) * 2019-11-27 2020-02-14 中南民族大学 双醋瑞因在用于舒张预收缩的气管平滑肌及治疗哮喘中的应用
CN113440503B (zh) * 2021-07-02 2022-03-18 温州医科大学附属口腔医院 超长效可控缓释介孔-透明质酸杂化靶向抗菌纳米材料及其制备方法、用途
CN115227664A (zh) * 2022-06-27 2022-10-25 苏州中化药品工业有限公司 一种双醋瑞因胶囊及其制备方法与应用
WO2024200722A1 (en) * 2023-03-28 2024-10-03 Tillotts Pharma Ag Solid oral dosage form comprising antibodies for sustained release in the lower gastrointestinal tract

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA761627B (en) * 1976-03-16 1978-01-25 C Friedmann Improvements in or relating to the treatment of arthritis
US5225192A (en) * 1988-10-17 1993-07-06 Vectorpharma International S.P.A. Poorly soluble medicaments supported on polymer substances in a form suitable for increasing their dissolving rate
US5569469A (en) * 1984-10-16 1996-10-29 Vectorpharma International, S.P.A. Poorly soluble medicaments supported on polymer substances in a form suitable for increasing their dissolving rate
IT1197316B (it) * 1986-10-01 1988-11-30 Proter Spa Formulazione galenica ad uso orale di derivati della reina a lento rilascio per impiego terapeutico
IT1230566B (it) * 1988-10-17 1991-10-28 Vectorpharma Int Farmaci poco solubili supportati su sostanze polimeriche in forma atta all'aumento della velocita' di dissoluzione
IT1241417B (it) * 1990-03-06 1994-01-14 Vectorpharma Int Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
US5840881A (en) * 1992-11-27 1998-11-24 Takeda Chemical Industries, Ltd. Composition containing a water-insoluble or slightly water-soluble compound with enhanced water-solubility
JP3459421B2 (ja) * 1992-12-23 2003-10-20 サイテック ソチエタ レスポンサビリタ リミテ 調節された開放医薬形の調製法及びそのようにして得られた医薬形
FR2757397B1 (fr) * 1996-12-23 1999-03-05 Mazal Pharma Composition pharmaceutique a base de rheine ou de diacerheine a biodisponibilite amelioree
US6197818B1 (en) * 1998-09-01 2001-03-06 Nanjing General Hospital Of Nanjing Command, Pla Drug for treating diabetic nephrosis
NZ530956A (en) * 2001-08-25 2005-08-26 Arakis Ltd Diacerin, in combination with other therapies, for the treatment of renal impairment and systemic lupus erythematosus (SLE)
FR2842738B1 (fr) * 2002-07-23 2006-02-10 Negma Lerads Utilisation d'une rheine pour la preparation d'un medicament pour le traitement de l'inflammation chronique, la prevention et le traitement du rejet des transplantations d'organes et de tissus
US20040186105A1 (en) * 2002-08-30 2004-09-23 Allenspach Carl T. Pharmaceutical composition exhibiting consistent drug release profile
AU2003230189A1 (en) * 2003-01-29 2004-08-23 Nitin Bhalachandra Dharmadhikari Oral controlled release pharmaceutical composition containing metaxalone as active agent
MXPA04009698A (es) * 2004-10-04 2006-04-05 Maria Elena Garcia Armenta Formulaciones farmaceuticas solidas conteniendo diacereina y meloxicam.
CN1748675A (zh) * 2005-07-11 2006-03-22 丛晓东 大黄酸类化合物的复合物及制备方法与治疗糖尿病的应用
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
CN100475201C (zh) * 2007-03-19 2009-04-08 上海慈瑞医药科技有限公司 二乙酰大黄酸缓释片的制备方法
CA2926563A1 (en) * 2007-09-27 2009-04-02 Wockhardt Research Centre Pharmaceutical compositions of rhein or diacerein
WO2009048940A2 (en) * 2007-10-08 2009-04-16 Dr. Reddy's Laboratories Ltd. Diacerein pharmaceutical formulations

Also Published As

Publication number Publication date
EP2349289A1 (en) 2011-08-03
JP2012506911A (ja) 2012-03-22
UY32204A (es) 2010-05-31
US20130156857A1 (en) 2013-06-20
US20100104651A1 (en) 2010-04-29
AU2009308958B2 (en) 2016-05-19
EP2349289B1 (en) 2016-07-13
CN102202673A (zh) 2011-09-28
AU2009308958A1 (en) 2010-05-06
CA2741846A1 (en) 2010-05-06
TWI473610B (zh) 2015-02-21
AR073918A1 (es) 2010-12-09
JP5642691B2 (ja) 2014-12-17
NZ592376A (en) 2012-12-21
KR20110081316A (ko) 2011-07-13
ES2585904T3 (es) 2016-10-10
RU2542461C2 (ru) 2015-02-20
CA2741846C (en) 2018-03-27
IL212483A0 (en) 2011-06-30
CN102202673B (zh) 2013-07-31
EP2349289A4 (en) 2013-12-04
RU2011121609A (ru) 2012-12-10
MX2011004395A (es) 2011-08-03
IL212483A (en) 2017-10-31
KR101718347B1 (ko) 2017-03-21
WO2010051296A1 (en) 2010-05-06
BRPI0920255A2 (pt) 2016-01-05
TW201018461A (en) 2010-05-16
SA109300644B1 (ar) 2014-10-28

Similar Documents

Publication Publication Date Title
PA8846801A1 (es) Composiciones farmacéuticas que contienen diacereína
DOP2019000287A (es) Anticuerpos monoclonales contra el inhibidor de la vía del factor tisular (tfpi)
SV2011003798A (es) Salicilatos acetilados con acidos grasos y sus usos
CY1119596T1 (el) Σταθερη φαρμακευτικη συνθεση και μεθοδοι χρησης αυτης
NI201100056A (es) Compuestos de multiheteroarilo como inhibidores de prostaglandina d sintasa hematopoyética y su uso para tratar enfermedades mediadas por prostaglandina d2.
ECSP19025350A (es) Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi)
ECSP12012097A (es) Derivados de fumarato de ácido graso y sus usos
CL2013000304A1 (es) Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
HN2011001810A (es) Sintesis de espirikpiridinas radiomarcadas con 18f a partir de precursores de tosilato y composiciones farmaceuticas estables de estas.
CR11648A (es) Composicion que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes acidas
GT201000023A (es) Nuevos derivados de 6-trialzolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met.
UY32456A (es) Composicion famaceutica, forma farmaceutica, procedimiento para su preparación, metodos de tratamiento
AR075442A1 (es) Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
BR112012012399B8 (pt) Composições para ruptura de biofilme, artigo ou dispositivo e método para ruptura de biofilmes
CR20110407A (es) Dicianopiridinas alquilamino-sustituidas y sus profármacos de éster de aminoácido
CR20110560A (es) Métodos de tratamiento para tumores sólidos
BR112012023421A2 (pt) composição farmacêutica para tratamento de aumento de pressão intraocular
BR112012020989A2 (pt) composições veterinárias
CL2008001835A1 (es) Uso de compuestos derivados de guaninas policiclicas para tratar la inflamacion; compuestos derivados de guanina; y compocicion farmaceutica que los comprende.
UY31788A (es) Formulación farmacéutica sólida con liberación retardada
BR112014020113A8 (pt) Composições farmacêuticas e método para diminuir a frequência de micção
CL2009001139A1 (es) Composicion que comprende un lisofosfolipido para tratar los efectos de la inflamacion.
AR098900A1 (es) Composiciones y métodos para el cuidado oral
MX2018015965A (es) Composicion de dos componentes.
CO2020006242A2 (es) Extractos de corteza de abedul que contienen betulina y su formulación